FrancophonIA/ELRC3.0 huggingface dataset:
English: • three additional studies compared Januvia with placebo when they were added to other antidiabetes medicines: glimepiride (another sulphonylurea), with or without metformin, in 441 patients; the combination of metformin and rosiglitazone (a PPAR-gamma agonist) in 278 patients; and a stable dose of insulin, with or without metformin, in 641 patients.
Slovenian: • v treh dodatnih študijah so zdravilo Januvia primerjali s placebom, obe zdravili so dodajali drugim zdravilom proti sladkorni bolezni; glimepiridu (drugi vrsti sulfonilsečnine), z metforminom ali brez njega, pri 441 bolnikih ali kombinaciji metformina in rosiglitazona (agonista PPAR-gama) pri 278 bolnikih ali ustaljenemu odmerku insulina, z metforminom ali brez njega, pri 641 bolnikih.
English: For the full list of all side effects reported with Januvia, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Januvia, glejte navodilo za uporabo.
English: When taken on their own, Januvia and metformin produced similar reductions in HbA1c levels, but the effectiveness of Januvia seemed to be slightly lower than that of metformin.
Slovenian: Ob samostojnem jemanju zdravila Januvia ali metformina so bila znižanja ravni HbA1c podobna, vendar je bilo zdravilo Januvia malenkost slabše učinkovito kot metformin.
English: The other study compared Januvia with metformin, used on their own, in 1,058 patients;
Slovenian: V drugi študiji so zdravilo Januvia primerjali z metforminom pri 1 058 bolnikih, ki so obe zdravili jemali samostojno;
English: • in combination with metformin or a PPAR-gamma agonist (a type of antidiabetes medicine) such as a thiazolidinedione, in patients who are not satisfactorily controlled on metformin or the PPARgamma agonist used on its own;
Slovenian: • v kombinaciji z metforminom ali agonistom PPAR-gama (vrsto zdravila proti sladkorni bolezni), kot je tiazolidinedion, pri bolnikih, katerih bolezen samo z metforminom ali agonistom PPAR-gama ni zadovoljivo nadzorovana;
English: What is Januvia used for?
Slovenian: Za kaj se zdravilo Januvia uporablja?
English: Januvia or placebo were used on their own in two studies involving 1,262 patients, as an add-on to metformin in one study involving 701 patients, and as an add-on to pioglitazone (a PPAR-gamma agonist) in one study involving 353 patients;
Slovenian: • v štirih študijah so zdravilo Januvia primerjali s placebom (zdravilom brez zdravilne učinkovine): zdravilo Januvia ali placebo so bolniki jemali samostojno v dveh študijah, ki sta vključevali 1 262 bolnikov, kot dodatek metforminu v eni študiji s 701 bolnikom in kot dodatek pioglitazonu (agonistu PPAR-gama) v eni študiji s 353 bolniki;
English: HbA1c levels were reduced by 1.03% after 18 weeks in patients adding Januvia to metformin and rosiglitazone, compared with a fall of 0.31% in those adding placebo.
Slovenian: Ravni HbA1c so bile po 18 tednih znižane za 1,03 % pri bolnikih, ki so zdravilo Januvia dodajali metforminu in rosiglitazonu, v primerjavi z znižanjem za 0,31 % pri tistih, ki so kot dodatek prejemali placebo.
English: How has Januvia been studied?
Slovenian: Kako je bilo zdravilo Januvia raziskano?
English: Finally, they were reduced by 0.59% in patients adding Januvia to insulin (with or without metformin), compared with a fall of 0.03% in those adding placebo.
Slovenian: Ravni so se znižale za 0,59 % pri bolnikih, ki so zdravilo Januvia dodajali insulinu (z metforminom ali brez njega) v primerjavi z zmanjšanjem za 0,03 % pri tistih, ki so kot dodatek jemali placebo.
English: In the additional studies, adding Januvia to glimepiride (with or without metformin) led to a reduction in HbA1c levels of 0.45% after 24 weeks, compared with an increase of 0.28% in the patients adding placebo.
Slovenian: V dodatnih študijah je dodajanje zdravila Januvia glimepiridu (z metforminom ali brez njega) po 24 tednih znižalo ravni HbA1c za 0,45 % v primerjavi s povečanjem za 0,28 % pri bolnikih, pri katerih so dodajali placebo.
English: How does Januvia work?
Slovenian: Kako zdravilo Januvia deluje?
English: What is Januvia?
Slovenian: Kaj je zdravilo Januvia?
English: How is Januvia used?
Slovenian: Kako se zdravilo Januvia uporablja?
English: One study compared Januvia with glipizide (a sulphonylurea), when they were used as an add-on to metformin in 1,172 patients.
Slovenian: V eni študiji so pri 1 172 bolnikih primerjali zdravilo Januvia z glipizidom (sulfonilsečnino), obe zdravili pa so dodajali metforminu.
English: When added to pioglitazone, Januvia reduced HbA1c levels by 0.85% after 24 weeks, compared with a fall of 0.15% in the patients adding placebo.
Slovenian: Če je bilo zdravilo Januvia dodano pioglitazonu, je po 24 tednih znižalo ravni HbA1c za 0,85 % v primerjavi z znižanjem za 0,15 % pri bolnikih, ki so kot dodatek jemali placebo.
English: Adding Januvia to metformin reduced HbA1c levels by 0.67% after 24 weeks, compared with a fall of 0.02% in the patients adding placebo.
Slovenian: Če je bilo zdravilo Januvia dodano metforminu, je po 24 tednih znižalo ravni HbA1c za 0,67 % v primerjavi z znižanjem za 0,02 % pri bolnikih, ki so kot dodatek jemali placebo.
English: 0.12% and 0.18%, respectively, in the patients taking placebo.
Slovenian: Pri bolnikih, ki so jemali placebo, pa so se povečale za 0,12 % oziroma 0,18 %.
English: Two of these studies included children.
Slovenian: Dve od teh študij sta vključevali otroke.
English: Opatanol has been studied in 688 patients in four main studies lasting between six and 14 weeks.
Slovenian: Zdravilo Opatanol so raziskali pri 688 bolnikih v štirih glavnih študijah, ki so trajale od 6 do 14 tednov.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Opatanol on 17 May 2002.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Opatanol, veljavno po vsej Evropski uniji, izdala 17. maja 2002.
English: Opatanol can be used for up to four months, if needed.
Slovenian: Zdravilo Opatanol se lahko po potrebi uporablja največ štiri mesece.
English: Opatanol is used in adults and children aged three years and older.
Slovenian: Zdravilo Opatanol se uporablja pri odraslih in otrocih, starejših od treh let.
English: The full EPAR for Opatanol can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Opatanol je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicine s/European public assessment reports.
English: Opatanol olopatadine
Slovenian: Opatanol olopatadin
English: This is a summary of the European public assessment report (EPAR) for Opatanol.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Opatanol.
English: These include itching, redness and swelling.
Slovenian: Ti simptomi vključujejo srbenje, pordelost in otekanje.
English: For more information about treatment with Opatanol, read the package leaflet (also part of the EPAR) or contact your doctor of pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Opatanol preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: The most common side effects with Opatanol (seen in between 1 and 10 patients in 100) are headache, dysgeusia (taste disturbances), eye pain, eye irritation, dry eyes, abnormal sensations in the eye, dry nose and fatigue (tiredness).
Slovenian: Najpogostejši neželeni učinki pri uporabi zdravila Opatanol (opaženi pri 1 do 10 bolnikih od 100) so glavobol, disgevzija (motnje okušanja), bolečine v očeh, draženje očesa, nenormalni občutki v očesu, suha sluznica v nosu in utrujenost.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Opatanol.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Opatanol, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: If another eye treatment is also being used, there should be a gap of five minutes between treatments; eye ointments should be administered last.
Slovenian: Če se istočasno izvaja še kako drugo zdravljenje očesa, je treba zdravila dajati z razmikom petih minut, pri čemer mazila za oči nanašamo nazadnje.
English: Opatanol was as effective as cromolyn sodium and as levocabastine.
Slovenian: Zdravilo Opatanol je bilo enako učinkovito kot natrijev kromoglikat in levokabastin.
English: The CHMP decided that Opatanol's benefits are greater than its risks for the treatment of ocular signs and symptoms of seasonal allergic conjunctivitis and recommended that it be given marketing authorisation.
Slovenian: CHMP je zaključil, da so koristi zdravila Opatanol večje od z njim povezanih tveganj pri zdravljenju očesnih znakov in simptomov sezonskega alergijskega konjunktivitisa, in priporočil, da se zanj izda dovoljenje za promet.
English: What benefit has Opatanol shown during the studies?
Slovenian: Kakšne koristi je zdravilo Opatanol izkazalo med raziskavami?
English: At lower pollen counts, there were no differences between the two treatments.
Slovenian: Pri nizkih koncentracijah cvetnega prahu razlik med obema zdraviloma ni bilo.
English: What is the risk associated with Opatanol?
Slovenian: Kakšna tveganja so povezana z zdravilom Opatanol?
English: Other information about Opatanol
Slovenian: Druge informacije o zdravilu Opatanol:
English: Therefore care should be taken by people who wear soft contact lenses.
Slovenian: Zato morajo biti osebe z mehkimi kontaktnimi lečami pri uporabi previdne.
English: Opatanol contains benzalkonium chloride, which is known to discolour soft contact lenses.
Slovenian: Zdravilo Opatanol vsebuje benzalkonijev klorid, katerega znana lastnost je, da razbarva mehke kontaktne leče.
English: Opatanol was compared with cromolyn sodium (another anti-allergy medicine), with levocabastine (another antihistamine) and, in two studies, with placebo (a dummy treatment).
Slovenian: Zdravilo Opatanol so primerjali z natrijevim kromoglikatom (drugo vrsto zdravila proti alergijam), z levokabastinom (drugo vrsto antihistaminskega zdravila), v dveh študijah pa so ga primerjali s placebom (zdravilom brez zdravilne učinkovine).
English: When compared with placebo, Opatanol was more effective only when pollen counts were taken into account, showing that the higher the level of pollen in the air, the greater the difference between the effects of Opatanol and those of placebo.
Slovenian: V primerjavi s placebom je bolj učinkovito le, če se upošteva tudi količina cvetnega prahu, pri čemer se je pokazalo, da je bila razlika med učinki zdravila Opatanol in placeba tem večja, čim večja je bila koncentracija cvetnega prahu v zraku.
English: For the full list of all side effects reported with Opatanol, see the Package Leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Opatanol, glejte navodilo za uporabo.
English: Opatanol is used to treat the eye symptoms of seasonal allergic conjunctivitis (inflammation of the eyes caused by pollen in patients with hayfever).
Slovenian: Zdravilo Opatanol se uporablja za zdravljenje očesnih simptomov sezonskega alergijskega konjunktivitisa (vnetja oči, ki ga pri bolnikih s senenim nahodom povzroča cvetni prah).
English: Why has Opatanol been approved?
Slovenian: Zakaj je bilo zdravilo Opatanol odobreno?
English: It is given as one drop into the affected eye(s) twice a day, given eight hours apart.
Slovenian: Odmerek zdravila Opatanol je ena kapljica v prizadeto oko (očesi) dvakrat na dan v osemurnih presledkih.
English: Olopatadine works by blocking the receptors on which histamine, a substance in the body that causes allergic symptoms, normally attaches itself.
Slovenian: Olopatadin deluje kot zaviralec receptorjev, na katere se običajno veže histamin, tj. snov v telesu, ki povzroča alergijske
English: The active substance in Opatanol, olopatadine, is an antihistamine.
Slovenian: Zdravilna učinkovina zdravila Opatanol je olopatadin, ki je antihistaminsko zdravilo.
English: How has Opatanol been studied?
Slovenian: Kako je bilo zdravilo Opatanol raziskano?
English: What is Opatanol used for?
Slovenian: Za kaj se zdravilo Opatanol uporablja?
English: What is Opatanol?
Slovenian: Kaj je zdravilo Opatanol?
English: Opatanol is a clear eye drop solution, which contains the active substance olopatadine.
Slovenian: Zdravilo Opatanol so kapljice za oko v obliki bistre raztopine, ki vsebuje zdravilno učinkovino olopatadin.
English: How does Opatanol work?
Slovenian: Kako zdravilo Opatanol deluje?
English: In all of the studies, the main measure of effectiveness was based on the degree of itching and redness in the eye. One of the placebo studies also looked at these symptoms in relation to pollen counts.
Slovenian: V vseh študijah je glavno merilo učinkovitosti temeljilo na intenzivnosti srbenja in pordelosti očesa.
English: How is Opatanol used?
Slovenian: Kako se zdravilo Opatanol uporablja?
English: 183 11 Täby Sweden
Slovenian: 183 11 Täby Švedska
English: 2710-444 Sintra Portugal
Slovenian: 2710-444 Sintra Portugalska
English: 0667 Oslo Norway
Slovenian: 0667 Oslo Norveška
English: Lumiracoxib 100 mg tablets
Slovenian: Lumiracoxib 100 mg tablete
English: ANNEX I LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES
Slovenian: DODATEK I SEZNAM IZMIŠLJENIH IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVIL, POTI UPORABE IN IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
English: U Nákladového nádraží 10 130 00 Praha 3
Slovenian: U Nákladového nádraží 10 130 00 Praga 3
English: Strength Pharmaceutical form Route of administration
Slovenian: Farmacevtska oblika Pot uporabe
English: Novartis Hungária Kft. 1114 Budapest Bartók Béla út 43-47 Hungary
Slovenian: Novartis Hungária Kft. 1114 Budapest Bartók Béla út 43-47 Madžarska
English: Novartis Healthcare A/S, Lyngbyvej 172, DK-2100 København Ø Denmark
Slovenian: Novartis Healthcare A/S, Lyngbyvej 172, DK-2100 København Ø Danska
English: 6824 DP Arnhem Nederland
Slovenian: 6824 DP Arnhem
English: Novartis Pharmaceuticals UK Limited,
Slovenian: Velika Britanija Novartis Pharmaceuticals UK Limited,
English: Novartis Pharmaceuticals UK Limited
Slovenian: Velika Britanija Novartis Pharmaceuticals UK Limited
English: Novartis Pharmaceuticals UK Ltd Frimley Business Park Frimley, Camberley Surrey GU-167-SR UK
Slovenian: Novartis Pharmaceuticals UK Ltd Frimley Business Park Frimley, Camberley Surrey GU-167-SR Velika Britanija
English: Novartis Pharmaceuticals UK Ltd. Frimley Business Park, Frimley, Camberly, GU16 7SR Surrey UK
Slovenian: Novartis Pharmaceuticals UK Ltd. Frimley Business Park, Frimley, Camberly, GU16 7SR Surrey Velika Britanija
English: Nederlands
Slovenian: Nizozemska
English: Novartis Pharma GmbH Brunner Straße 59 1235 Wien
Slovenian: Novartis Pharma GmbH Brunner Straße 59 1235 Dunaj
English: Novartis Finland Oy, Metsänneidonkuja 10, FI-02130, Espoo Finland
Slovenian: Novartis Finland Oy, Metsänneidonkuja 10, FI-02130, Espoo Finska
English: Belgium Novartis Pharma NV Medialaan 40 bus 1
Slovenian: Novartis Pharma NV Medialaan 40 bus 1 B-1800 Vilvoorde Belgija
English: Member State Marketing Authorisation Holder (Invented) name
Slovenian: Država članica Imetnik dovoljenja za promet z zdravilom
English: Novartis Finland Oy, Metsanneidonkuja-10, FIN-02130 Espoo Finland
Slovenian: Novartis Finland Oy, Metsanneidonkuja-10, FIN-02130 Espoo Litva
English: U Nákladového nádraží 10 130 00 Prague 3
Slovenian: Novartis s.r.o., Nagano III. U Nákladového nádraží 10 130 00 Praga 3
English: 90429 Nürnberg Germany
Slovenian: 90429 Nürnberg Nemčija
English: D-90429 Nuernberg Germany
Slovenian: D-90429 Nuernberg Nemčija
English: Novartis Pharma B.V. Raapopseweg 1
Slovenian: Nizozemska Novartis Pharma B.V.
English: Frimley Business Park Frimley, Camberley Surrey GU16 7SR UK
Slovenian: Surrey GU16 7SR
English: D-90429 Nurnberg Germany
Slovenian: D-90429 Nürnberg Nemčija
English: {Name and address} {tel} {fax} {e-mail}
Slovenian: {Ime in naslov} {tel.} {faks} {e-pošta}
English: An effect in man cannot be excluded.
Slovenian: Vpliva pri človeku ni mogoče izključiti.
English: Number (%) of patients who had died.
Slovenian: Število (%) umrlih bolnic.
English: It is a long-term treatment and you may need to take it for several years.
Slovenian: To je dolgotrajno zdravljenje in morda boste zdravilo morali jemati več let.
English: Your tablets could harm them.
Slovenian: Te tablete jim lahko škodujejo.
English: Keep your tablets in a safe place where children cannot see or reach them.
Slovenian: Tablete shranjujte na varnem mestu, kjer jih otroci ne morejo videti ali doseči.
English: 51689 Reims Cedex France
Slovenian: 51689 Reims Cedex Francija
English: Food slightly decreases the rate but not the extent of absorption.
Slovenian: Hrana nekoliko zmanjša hitrost absorpcije, ne pa njenega obsega.
English: After the Commission Decision the Member State Competent Authorities, in liaison with the Reference Member State, will update the product information as required.
Slovenian: Po odločbi Komisije bodo pristojni organi držav članic, v povezavi z referenčno državo članico posodobili podatke o zdravilu, kot je potrebno.
English: This would be seen in a blood test.
Slovenian: To se pokaže s preiskavo krvi.
English: Long-term safety data in children and adolescents are not available.
Slovenian: Dolgoročnih podatkov o varnosti pri otrocih in mladostnikih ni.
English: Final height data were not available.
Slovenian: Podatki o končni telesni višini niso bili na voljo.
English: If you forget to take a dose, just take your next dose as normal.
Slovenian: Če ste pozabili vzeti odmerek, zgolj vzemite naslednji odmerek kot po navadi.
English: Detailed information on this medicine is available on the web site of {MA/Agency}
Slovenian: Podrobne informacije o zdravilu so objavljene na spletni strani {DČ/agencija}
English: Corticoid supplements are therefore not needed.
Slovenian: Dodajanje kortikoidov zato ni potrebno.
English: - if you have problems with your liver or kidneys.
Slovenian: - če imate težave z jetri ali ledvicami.
English: Keep your tablets in the container they came in.
Slovenian: Tablete shranjujte v vsebniku, v katerem ste jih dobili.
English: All patients received treatment with vitamin D and calcium.
Slovenian: Vse bolnice so prejemale zdravljenje z vitaminom D in kalcijem.
English: If bleeding persists, further evaluation should be considered.
Slovenian: Če krvavitev traja, je potrebno dodatno ovrednotenje.
English: Do not take a double dose (two doses at the same time) to make up for a forgotten dose.
Slovenian: Ne vzemite dvojnega odmerka (dveh odmerkov hkrati), če ste pozabili vzeti prejšnji odmerek.
English: General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.
Slovenian: Indicirana je splošna podporna oskrba, vključno s pogostim nadziranjem vitalnih znakov in natančnim opazovanjem bolnika.
English: - if you are pregnant or breast-feeding (see the section called ‘Pregnancy and breast-feeding').
Slovenian: - če ste noseči ali če dojite (glejte poglavje "Nosečnost in dojenje").
English: This may lower the mineral content of your bones.
Slovenian: To lahko zmanjša vsebnost mineralov v kosteh.
English: Your bones may be less strong and may be more likely to fracture.
Slovenian: Kosti lahko postanejo manj čvrste in poveča se verjetnost zlomov.
English: • Bleeding from the vagina (usually in the first few weeks of treatment - if the bleeding continues, talk to your doctor).
Slovenian: • krvavitev iz nožnice (po navadi v prvih nekaj tednih zdravljenja - če se krvavitev nadaljuje, se posvetujte z zdravnikom)
English: This is known as ‘angioedema'.
Slovenian: To je znano kot "angioedem".
English: However, the majority of these events occurred in patients with identifiable risk factors for the development of the condition.
Slovenian: Vendar se je večina teh primerov pojavila pri bolnikih s prepoznavnimi dejavniki tveganja za pojav te motnje.
English: Thirteen out of the 14 patients enrolled completed 12 months of combination treatment (one patient was lost to follow-up).
Slovenian: Dvanajstmesečno kombinirano zdravljenje je dokončalo 13 od 14 vključenih bolnikov (en bolnik se je izgubil spremljanju).
English: These effects occurred at clinically relevant doses.
Slovenian: Ti učinki so se pojavili pri klinično pomembnih odmerkih.
English: Multiple dose toxicity studies utilized rats and dogs.
Slovenian: V študijah toksičnosti več odmerkov so uporabili podgane in pse.
English: Estrone is subsequently converted to estradiol.
Slovenian: Estron se nato spremeni v estradiol.
English: There is no specific antidote to overdose and treatment must be symptomatic.
Slovenian: Specifičnega antidota za preveliko odmerjanje ni in zdravljenje mora biti simptomatsko.
English: Treatment should be based on a benefit-risk evaluation for the individual patient.
Slovenian: Zdravljenje mora temeljiti na oceni koristi in tveganja za vsako posamezno bolnico.
English: Very rarely symptoms of joint, stomach, and kidney pain may occur; this is known as ‘Henoch-Schönlein purpura'.
Slovenian: Zelo redko se lahko pojavijo simptomi v sklepih, želodcu in bolečine ledveno; to imenujemo "Henoch-Schönleinova purpura".
English: Treatment or prophylaxis for osteoporosis should be initiated as appropriate and carefully monitored.
Slovenian: Zdravljenje ali profilakso osteoporoze je treba začeti, kot je ustrezno, in ju natančno nadzirati.
English: The effect of potent CYP inhibitors is unknown.
Slovenian: Učinek močnih zaviralcev CYP ni znan.
English: Frequency groupings are defined according to the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to <1/1,000), and very rare (<1/10,000).
Slovenian: Skupine pogostnosti so opredeljene po naslednjem dogovoru: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) in zelo redki (< 1/10.000).
English: - if you have ever had a condition that affects the strength of your bones (osteoporosis).
Slovenian: - če ste kdaj imeli bolezen, ki prizadene čvrstost kosti (osteoporozo).
English: The rate of prolonged (more than 24 weeks) stable disease, the rate of progression, and survival were also calculated.
Slovenian: Izračunani so bili tudi delež dolgotrajno stabilne bolezni (več kot 24 tednov), delež napredovanj in preživetje.
English: Two further similar trials (GABG/ARNO 95 and ITA), in one of which patients had received surgery and chemotherapy, as well as a combined analysis of ABCSG 8 and GABG/ARNO 95, supported these results.
Slovenian: Dve nadaljnji podobni preskušanji (GABG/ARNO 95 in ITA), v enem od katerih so bolnice zdravili z operacijo in kemoterapijo, ter kombinirana analiza ABCSG 8 in GABG/ARNO 95 potrjujejo te rezultate.
English: There were too few deaths occurring across treatment groups of both trials to draw conclusions on overall survival differences.
Slovenian: Smrti je bilo v terapevtskih skupinah obeh preskušanj premalo, da bi bilo mogoče sklepati o razliki v celokupnem v preživetju.
English: You should talk to your doctor about the risks and treatment options.
Slovenian: Z zdravnikom se posvetujte o tveganjih in o drugih možnostih zdravljenja.
English: Measured mean plasma concentrations were 44.4 (±14.7) ng/ml and 165 (±90) ng/ml respectively.
Slovenian: Izmerjena povprečna koncentracija v plazmi je bila 44,4 (± 14,7) ng/ml in 165 (± 90) ng/ml.
English: If any of these happen to you, call an ambulance or see a doctor straight away - you may need urgent medical treatment.
Slovenian: Če se vam pojavi kaj od tega, takoj pokličite reševalce ali pojdite k zdravniku - morda potrebujete nujno zdravniško pomoč.